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ABSTRACT 
 
We identify a mutation (D262N) in the erythroid-affliated transcriptional 
repressor GFI1B, in an acute myeloid leukemia (AML) patient with antecedent 
myelodysplastic syndrome (MDS). The GFI1B-D262N mutant functionally 
antagonizes the transcriptional activity of wild-type GFI1B. GFI1B-D262N 
promoted myelomonocytic versus erythroid output from primary human 
hematopoietic precursors and enhanced cell survival of both normal and MDS 
derived precursors. Re-analysis of AML transcriptome data identifies a distinct 
group of patients in whom expression of wild-type GFI1B and SPI1 (PU.1) have 
an inverse pattern. In delineating this GFI1B-SPI1 relationship we show that (i) 
SPI1 is a direct target of GFI1B, (ii) expression of GFI1B-D262N produces 
elevated expression of SPI1, and (iii) SPI1-knockdown restores balanced 
lineage output from GFI1B-D262N-expressing precursors. These results table 
the SPI1-GFI1B transcriptional network as an important regulatory axis in AML 
as well as in the development of erythroid versus myelomonocytic cell fate. 
 
 
Keywords: GFI1B; SPI1; PU.1; transcriptional networks; acute myeloid 
leukemia; myelodysplastic syndrome. 
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INTRODUCTION 
Transcription factor mutation is a major cause of cell fate dysregulation in 
leukemia. Indeed many key regulators of hematopoiesis were identified through 
analysis of leukemia patients.1 Myelodysplastic syndromes (MDS) by contrast, 
are acquired clonal diseases regarded broadly as 'pre-leukemic' conditions that 
can be conservatively managed. However, approximately 10% of all MDS cases 
evolve into acute myeloid leukemia (AML) within the course of two years.2 Key 
challenges in the field are to understand how individual regulators control cell 
fate at the level of lineage choice, self-renewal, cell cycle or survival, how 
different regulators interact in transcriptional networks and how circuit behavior 
is altered in leukemia.3,4  
Transcription factor GFI1B was identified by sequence homology with oncogene 
GFI1 (Growth Factor Independence 1).5 Both GFI1 and GFI1B have six C-
terminal C2H2 zinc-fingers and an N-terminal SNAG transcriptional repression 
domain.5–7 
In mice, Gfi1 is essential for neutrophil differentiation8,9 and in humans severe 
congenital neutropenia is associated with mutations in GFI1.10 Gfi1 is also 
required for B and T lymphopoiesis.11,12 In contrast knockout mice have 
demonstrated that Gfi1b is required for development of both erythroid and 
megakaryocytic lineages,13 but the mechanism is not understood.14 Loss of 
Gfi1b in adult mice increases absolute numbers of hematopoietic stem cells 
(HSC), these are less quiescent than wild type HSCs.15 In partial agreement 
with the mouse models, human congenital mutations of GFI1B produce 
hemorrhagic conditions with abnormal platelet function.16,17 
Against this backdrop, we have studied a previously unreported acquired point 
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mutation (D262N) in the transcription factor GFI1B in a patient with AML arising 
from an antecedent MDS and explored its biological properties. 
This mutation leads to an amino acid change in the fourth zinc finger domain 
and results in a mutant protein that when expressed in normal human Common 
Myeloid Progenitors (CMPs) skews lineage output towards myelopoiesis. 
Expression of GFI1B (D262N) in human bone marrow (BM) cells from healthy 
individuals and other MDS patients promotes their survival. We show that these 
effects are mediated by upregulation of SPI1 (PU.1). 
 
SPI1 is a critical factor in blood cell differentiation.18,19 In order to form 
macrophages, granulocytes and B cells SPI1 levels must be exquisitely 
regulated.20,21 Our data, point to a SPI1/GFI1B axis regulating erythroid/myeloid 
commitment, which when dysregulated may play a role in leukemogenesis. 
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MATERIAL AND METHODS 
 
MATERIAL AND METHODS 
Human Material  
Human material and clinical information was obtained with informed consent 
and approval of institutional ethics committee. 
 
Point mutation analysis 
PCR fragments were analyzed by DHPLC as before (Supplementary Table 1).22 
 
Target Region Capture Sequencing 
Genomic DNA was randomly fragmented by Covaris (Woburn). DNA was 
amplified by ligation-mediated PCR (LM-PCR), purified, and hybridized to the 
NimbleGen (Roche) human custom array. High-throughput sequencing was 
performed with Hiseq2000 (Illumina). 
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Cloning 
GFI1B cDNA was amplified with primers indicated in Supplementary Table 2, 
cloned in pGEM-T easy vector and sequenced. Point mutation was introduced 
by PCR. Wild-type or mutated coding cDNA was amplified from this plasmid 
with oligonucleotides shown in Supplementary Table 2 and cloned into 
pHRSINCSGW lentivirus vector, expressing green fluorescent protein (GFP).23 
The SPI1 hairpin has been published,24 it was cloned into the SLX vector,23 with 
or without wild-type or mutant GFI1B. 
Lentivirus 
Were prepared as described.25 
 
Enrichment of hematopoietic stem and progenitors 
Enrichment of CD34+ cells obtained from G-CSF mobilized adult human 
peripheral blood from patients undergoing autograft procedures for non-
hematological disorders was by magnetic selection (Miltenyi Biotec). 
Cord blood progenitors were isolated as described.26 
Mobilised adult CD34+ cells and cord blood derived hematopoietic progenitors 
were maintained in MyeloCult® H5100 (StemCell Technologies) supplemented 
with 100ng/mL each human SCF, TPO, Flt3L (Peprotech). 
 
Isolation of lentivirally transduced cells 
 
Three days after lentiviral infection transduced cells were labeled with APC anti 
human CD34 (Cat 345802, BD Pharmingen) and CD34+/GFP+ cells were 
isolated using a Mo-Flo cell sorter (Dako). 
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MDS cell culture 
Bone marrow mononuclear cells were enriched for CD34+ cells by magnetic 
separation and cultured in MyeloCult® H5100 with 10% (v/v) HS-5 conditioned 
medium, human SCF and IL-3 (both 50 ng/ml, Peprotech). 
 
Methylcellulose Colony-Forming Cell (CFC) assays 
CFC assays were in MethoCult H4436 (StemCell Technologies), 15 days. We 
performed 2 biological replicates for each experiment and plated 1000 cells in 
each experiment. 
 
Liquid differentiation assays 
These were performed in Myelocult® H5100 supplemented with human 
cytokines: SCF, FLT3L (both 50 ng/ml), IL-3, IL-6, GM-CSF, M-CSF (all 10 
ng/ml): (Peprotech); G-CSF (0.1 MUI) (Ratiopharm); EPO (Amgen) (100 ng/ml)  
 
Chromatin immunoprecipitation (ChIP) assay 
ChIPs and immunoprecipitated DNA analysis were performed as previously 
described.27–29 SPI1 promoter primers and probes are shown in Supplementary 
Table 3. 
 
AML patients gene expression profiling and data analysis. 
This has been published (www.ncbi.nlm.nih.gov/geo, GSE1159).30 
 
Computational model  
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We applied deterministic rate equations.3,31 Additional information can be found 
in the Supplementary Methods and Supplementary Figure 1. 
 
RESULTS 
 
A GFI1B zinc finger mutation arising on transformation of MDS into AML  
 
Using DHPLC , we analyzed the GFI1B coding regions in DNA from the 
diagnostic bone marrow of 69 previously described patients with AML.22 In this 
analysis, we identified a case with an abnormal pattern (Figure 1A). 
Immunophenotyping data from the diagnostic bone marrow aspirate (which 
showed 48% blasts) are provided in Supplementary Table 4. Bacterial cloning 
allowed the identification of a novel G>A mutation in exon six (position +3198 
from the start codon, chromosome nine coordinate 135865264 GRCh37/hg19 
assembly, NM_004188.5:c.784G>A), Figure 1B, in 12% of clones. This 
mutation is predicted to lead to an Asp (D) to Asn (N) transversion at aa262 
(p.Asp262Asn), in the phylogenetically conserved fourth zinc finger motif of both 
GFI1B and GFI1 (Figure 1C). To accurately quantify the proportion of mutated 
DNA in the marrow, we performed a target region capture and next generation 
sequencing (NGS) of coordinates 135851000-135883000 chromosome nine 
GRCh37/hg19 assembly. This  identifies the mutation in 13% of the total 
analysed DNA, corresponding to 26% of marrow cellularity. It is therefore, is a 
major clone in the leukemia (Supplementary Table 5). In contrast, we were 
unable to detect the mutation in samples taken some 18 months previously, 
when the patient initially presented with MDS, refractory anemia with excess 
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blasts (RAEB), (Figure 1D-F). This suggests that in this case, the acquisition of 
D262N is associated with disease progression. 
 
GFI1B D262N impairs the function of the wild-type GFI1B. 
To evaluate the impact of the GFI1B D262N (GFI1Bm) mutation we generated 
lentiviral vectors containing GFI1B and GFI1Bm under the control of either the 
spleen focus forming virus (CSI) or the Wiskott Aldrich Syndrome Protein 
promoters (CWI) allowing us to study the effects of relatively high (CSI) or low 
(CWI) levels of transgene over-expression (Figure 2A). Transduced cells were 
marked by an emerald-GFP reporter. GFP positive primary cells and cell lines 
were sorted and evaluated for expression of GFI1B targets. 
 
GFI1B down-regulates its own expression.28,32 Consistent with this, we 
observed reduced levels of endogenous GFI1B mRNA after enforced 
expression of a GFI1B transgene in the leukemic cell line K562. This effect was 
proportional to transgene levels (Figure 2B) and similar results were obtained in 
primary CD34+ BM cells (Figure 2C). Enforced expression of GFI1Bm, in 
contrast, failed to repress endogenous GFI1B; indeed transcript levels 
increased (Figure 2B, C). This effect was magnified by the increase in GFI1B 
expression (Figure 2B). These data are consistent with the notion that 
expression of GFI1Bm interferes with the repressor functions of wild-type 
GFI1B. 
Functional antagonism of GFI1Bm on GFI1B was also observed in the 
derepression of other known GFI1B targets (Figure 2D).33–35 
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To explore mechanism of the differential effect of GFI1B and GFI1Bm on gene 
expression, we studied epigenetic marks within the endogenous GFI1B (Figure 
2E) locus by ChIP in the hematopoietic cell line K562. Histone H3K4me3, 
associated with active transcription,36 was significantly reduced at, and 
immediately downstream of, the endogenous promoter in cells transduced with 
GFI1B, but not GFI1Bm (Figure 2F). Consistent with previous observations,28,37 
H3K4me2 did not change (Figure 2G). 
 
Taken together these results indicate that GFI1B D262N lacks the 
transcriptional repressor functions associated with the wild-type protein and that 
this alters histone methylation. 
 
GFI1B D262N impacts lineage output from human primary hematopoietic 
cells  
We tested the functional impact of GFI1Bm in hematopoiesis, by transducing 
primitive CD34+ cells derived from adult bone marrow with CWI or CSI based 
lentiviral vectors (Figure 3A) and assessing cell fate in vitro. 
When CD34+ cells expressing GFI1Bm were maintained in liquid culture 
conditions that support multi-lineage differentiation, we observed a decrease in 
erythroid and an increase in myeloid output compared to cells transduced with 
wild-type GFI1B. This was assessed by expression of  erythroid  markers CD36 
and CD235a and the myeloid marker CD13, Figure 3B. 
Human CD34+ cells comprise several primitive hematopoietic progenitor types. 
In order to further define the cells in which GFI1Bm has functional impact, we 
transduced cord-blood derived CMP (defined as CD34+38+10-7-135+45RA-, 
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Supplementary Figure 2). Consistent with our initial observations, GFI1Bm 
expression skewed lineage output towards myeloid in this compartment (Figure 
3C). This shows that GFI1B D262N has a biological impact in highly purified 
bipotential progenitors. This skewing of lineage output was also seen in colony 
assays in methylcellulose with the same cytokines under conditions where total 
colony numbers were unaltered (Figure 3D, Supplementary Figure 3).  
We next explored the impact of GFI1Bm on progenitors under conditions that 
promote erythroid output. These results are presented in Figure 3E and show 
that expression of GFI1Bm also produces a reduction in erythroid output. 
Transduction with the CWI construct driving lower expression levels revealed 
that this phenomenon was partly GFI1Bm dose dependent. The persistence of 
the erythroid differentiation bias under this experimental setting, which is closer 
to the physiological conditions, underlines the in vivo relevance of this finding. 
GFI1B exhibits pro-apoptotic activity in human CD34+ cells.38 Consistent with 
GFI1Bm's functional antagonism of wild-type GFI1B activity, GFI1Bm enhanced 
the resistance of normal bone marrow CD34+ cells to apoptosis when 
incubated in the absence of cytokines (Figure 3F, G). Similarly, GFI1Bm also 
enhanced the resistance of CD34+ cells from MDS patients to apoptosis 
(Supplementary Figure 4 and Supplementary Table 6). Interestingly, colonies 
derived from cells transduced with GFI1B appeared smaller than those from 
GFI1Bm transduced cells (data not shown). 
 
These data show that GFI1B D262N promotes the survival of normal human 
BM CD34+ cells and skews lineage output towards myeloid under conditions 
that support multilineage differentiation, implying a link between this mutation 
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and the malignant phenotype. 
 
Cross regulatory relationships of GFI1B and SPI1 in normal and AML cells 
 
Although the GFI1B mutation we report is  thus far restricted to a single case, 
we reasoned that the pathways that it dysregulates could have a wider role in 
AML. In support of this, analysis of transcriptional profiles from 285 previously 
characterized AMLs30 revealed a striking inverse relationship in the patterns of 
GFI1B and SPI1 expression (Figure 4A). This suggests that GFI1B antagonizes 
SPI1 expression and that, simplistically at least, GFI1Bm could increase SPI1 
levels. However, the presence of wild type and mutant GFI1B alleles in the 
same cell complicates the situation (Figure 4B, C) and, therefore, we initially 
analyzed the behavior of this circuit in silico using a deterministic rate equation 
approach,3,31 (Supplementary Methods, Supplementary Figure 1 and 
Supplementary Table 7). Computational analysis indicates that even 
heterozygous expression of GFI1Bm enhances SPI1 expression (Figure 4D). 
Manipulation of GFI1B expression in K562 cells provides concrete experimental 
evidence for this prediction (Figure 4E). Studies in primary human cells showed 
a similar trend (Figure 4F), small divergences between the two most likely 
reflect the inherent heterogeneity in primary cells. 
 
Gfi1b binding to the Spi1 promoter in mouse,39 suggests that the effects on 
SPI1 expression that we observed may in part stem from a direct regulation of 
SPI1 locus by GFI1B. We found a conserved GFI1B binding sequence at the 
same location in the human promoter (Figure 4G), and confirmed by ChIP that 
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GFI1B binds to this site (Figure 4H). 
 
We next explored the AML data set to ask what other molecular features 
correlated with high levels of SPI1 expression and observed a strong correlation 
with CD4 (Figure 5A). Interestingly, the leukemic blasts in the index case, were 
CD4+ (Supplementary Table 4). We have previously shown CD4 to be direct 
target of Spi1 in multipotent mouse progenitor cells as well as in their 
myelomonocytic-differentiated progeny,40 and consistent with our hypothesis 
that GFI1Bm in part contributes to leukemogenesis though manipulation of the 
SPI1 programme we demonstrated that forced expression of GFI1Bm increases 
cell-surface CD4 expression in normal human CD34+ cells (Figure 5B, C). 
 
The effects of GFI1Bm may be in part due to the actions of transcription factors 
other than SPI1, and this could explain small deviations from the predictions of 
our model. To explore this possibility, we re-analysed the AML data, and noted 
both a positive relationship between the expression of GFI1B and the 
megakaryocytic/erythroid affiliated transcription factor MLLT341 (Figure 5D), and 
an inverse relationship between SPI1 and MLLT3. Consistent with this, in both a 
hematopoietic cell line and in primary cells, GFI1B increased and GFI1Bm 
reduced MLLT3 expression (Figure 5E and F). 
 
Taken together, these results suggest that high level SPI1 expression is 
associated with myelomonocytic affiliated AML samples. Expression of GFI1Bm 
dramatically enhances SPI1 expression and also results in up-regulation of the 
SPI1 target gene CD4. Interference with endogenous GFI1B activity is a 
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plausible explanation for these findings. 
 
The effects of GFI1B D262N are routed through SPI1 
 
We tested whether the effects of GFI1Bm were mediated by increased SPI1 
expression using a previously validated shRNA sequence.24 With this reagent, 
we achieved knockdown of SPI1 RNA to approximately 15% of its starting level 
in adult human primary cells (CD13+/235-) (Figure 6A). We constructed a 
lentiviral vector containing this short-hairpin as well as either GFI1B or GFI1Bm 
under the control of an SFFV promoter. This strategy ensured co-expression 
within the same cells of the SPI1 shRNA and either the wild type or mutant 
GFI1B. These vectors were validated in K562 cells where SPI1 and 
GFI1B/GFI1Bm expression were simultaneously assessed (Figure 6B). The 
relative levels of SPI1 and GFI1B/GFI1Bm expression observed are consistent 
with the cross regulatory relationships we have proposed. Thus, total GFI1B 
levels are lower than those of GFI1Bm, consistent with its negative-
autoregulatory behaviour. In contrast the extent of SPI1 knockdown observed is 
more marked in the GFI1B than the GFI1Bm setting, which is consistent with 
the proposed repressive role of GFI1B on SPI1. 
 
We next transduced both adult mobilized CD34+ cells and cord blood derived 
CMPs with these 'dual' vectors and cultured them post transduction under 
cytokine conditions supportive of multineage differentiation, which was 
assessed with lineage-affiliated cell surface markers. Strikingly, and in both 
primary cell settings, knockdown of SPI1 activity, almost completely abrogated 
16 
 
the lineage impact of GFI1Bm expression (Figure 6, C, D and E). Similarly, the 
effect of GFI1Bm on CD4 expression could be attenuated by SPI1 knockdown 
(Figure 6F). SPI1 has a half-life of approximately 70 hours.42 We sorted 
CD34+/GFP+ cells 72 hours after lentivirus transduction and then cultured them 
for 5-6 days under differentaiting conditions before analyzing only the GFP+ 
cells. Thus, our experiments were performed more than 3 SPI1 protein half lives 
after viral transduction, thereby excluding the possibility residual endogenous 
protein could be interfering in our experiments. These results suggest that most 
- if not all - of GFI1Bm's activity in this experimental setting is routed through the 
master regulator SPI1. 
 
DISCUSSION 
 
Human cancer cells carry an extensive number of “driver” and neutral or 
“passenger” mutations.43 Therefore, the frequent descriptions of mutations in 
malignant samples, do not necessarily imply a causal relationship between a 
genetic defect and a clinical phenotype. Establishing a link between such 
mutations and the malignant process requires functional assessment of their 
biological impact in the context of appropriate normal and malignant primary 
cells. Against this backdrop, we have identified a human GFI1B point mutation 
(D262N) in AML and explored its biological properties in both normal and pre-
leukemic (MDS) cells. We show that (i) the mutant GFI1B molecule impairs the 
function of wild-type GFI1B, (ii) its expression in primary hematopoietic 
progenitor cells of bone marrow or cord blood derivation, leads to a block in 
erythroid differentiation, an increase in myeloid output and a reduction in cell 
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death and (iii) it enhances cell survival of primary MDS samples under 
conditions of limiting growth factor availability. Taken together these findings 
establish a causal link between this mutation and the malignant process. 
Through survey of gene expression data from primary AMLs we noted that 
leukemias with low GFI1B levels displayed high expression of SPI1, prompting 
us to test, and indeed prove, the hypothesis that the effects of this new mutation 
in GFI1B are routed through the nodal master regulator SPI1. From a 
mechanistic and transcriptional network perspective, these results suggest that 
pathways leading to enhanced expression of SPI1 may have a broad role in the 
pathogenesis of AML. 
 
High levels of expression of GFI1B have been observed in some patients with 
leukemia and also in leukemic cell lines.44,45 However, the recent findings 
showing that Gfi1b is a direct repressor of oncogene Meis1 supports the notion 
that GFI1B can be involved in leukemia when its repressor function is 
abolished.46 Other genes including SPI1.47-50 are associated with hematological 
malignancy both when up regulated and functionally inactivated This can be the 
case in proteins in which dose can have a deep impact on cell function and 
could explain the tight regulation of GFI1B expression level.22 
 
Spi1 over expression produces erythroleukemia in mice.47 Furthermore, SPI1 is 
over expressed in human KMT2A (MLL)-rearranged AMLs when compared to 
normal bone marrow CD34 cells,49 and in mice, it has been shown to play an 
essential role in the initiation and maintenance of these leukemias.49,50 A subset 
of SPI1 target genes relevant to KMT2A leukemias is also regulated by 
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MEIS1.49 That GFI1B regulates both SPI1 and MEIS1 places it upstream in the 
same leukemogenic pathway. Therefore, our data uncover a previously 
unrecognized route to the dysregulation of SPI1 in AML. Recently, mutations in 
SPI1 have been found in 3 of 31 (10%) KMT2A-rearranged and 1 in 384 non-
KMT2A-rearranged AMLs.51 Two of the mutations in KMT2A leukemias were 
associated with reduced expression of SPI1 target genes. However, these 
authors did not find SPI1 among the genes whose expression level is altered in 
KMT2A AML compared to other AMLs.51 These data underline the 
heterogeneity of AML, in which seemingly disparate subsets of patients may 
share specific transcriptional networks that could be therapeutically targeted.  
 
The mutation described here appeared at the evolution of AML from a case of 
MDS, and it was not detectable during this earlier phase of the disease. NGS 
indicates that it  is present in  54% of leukemic cells. It is known that clonal 
heterogeneity is common in AML, importantly, different subclones are relevant 
at different stages of the disease,52 and similarly new clonal events almost 
certainly drive the evolution of MDS to AML. 
 
Although this is an infrequent mutation, we have demonstrated clear biological 
activity and a link between GFIB mutations and SPI1 deregulation. Our findings 
reinforce the importance of the SPI1 pathway in leukemogenesis.  
 
 
CONCLUSIONS 
Our  data link GFI1B to both the myeloid and erythroid transcriptional networks 
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by its repression of SPI1 and promotion of  MLLT3 expression.  This increases 
the understanding of its role in lineage specification and its potential in 
promoting blood malignancy. Our clinical findings and experimental data show 
that the GFI1B D262N mutant plays a role in AML in humans and does so 
primarily through the agency of the master transcriptional regulator SPI1, 
reflecting the physiological function of GFI1B in SPI1 regulation. 
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FIGURE LEGENDS 
 
Figure 1. A point mutation in GFI1B alters a conserved amino acid in a 
patient with AML arising from MDS. Analysis of the presentation MDS 
suggests the GFI1B mutation appeared on leukemic transformation. 
(A) DHPLC traces from the index patient at the diagnosis of AML (red) and a 
normal control (blue). The diagram on the top represents the result after running 
the samples at 63ºC and at the bottom are the tracings performing the 
experiment at 65ºC. This is a representative result from four independent 
experiments.  
(B) Sequence analysis of the patient at the diagnosis of AML. Top, direct 
sequence of PCR products; middle, mutant allele after subcloning the PCR 
products (2 mutant clones in 17 total analyzed were found two independent 
experiments); bottom, wild-type allele. Arrow indicates the mutation.  
(C) Protein sequence alignment of GFI1B orthologs including the mutated 
amino acid (arrow). Human (Homo sapiens); Mouse (Mus musculus); Rat 
(Rattus norvegicus); Dog (Canis familiaris); Opossum (Monodelphis domestica); 
Platypus (Ornithorhynchus anatinus); Chicken (Gallus gallus); Anole lizard 
(Anolis carolinensis); Xenopus (Xenopus tropicalis); Fugu (Takifugu rubripes); C 
elegans (Caenorhabditis elegans); D melanogaster (Drosophila melanogaster); 
sens-2 (senseless-2); sens (senseless). 
(D) Photomicrographs of peripheral blood (PB) slides (Wright’s stain) from the 
MDS diagnostic sample of the index patient showing anisopoikilocytosis, 
dysplastic features and circulating myeloblasts consistent with the diagnosis of 
RAEB. Images have been taken with an Olympus BX 60 microscope and Q 
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imaging, QICAM, camera and Openlab 5.5.1 software. Top, 40x and bottom 
100x objective, respectively. 
(E) DHPLC tracing of archival DNA from the index patient at the time of 
diagnosis of MDS (red) and a normal control (blue). The plot on the top shows 
the result after running the samples at 63ºC and at the bottom are the records 
performing the experiment at 65ºC. The abnormal peaks subsequently 
observed when the patient developed  AML were not present at this point. 
(F) Direct sequencing at MDS diagnosis. The arrow indicates the base where 
the mutation was found, undetected in this experiment. 
 
Figure 2 GFI1B D262N impairs the function of the normal protein. 
(A) Western blot of total protein extracts from K562 cells transduced with either 
GFI1B or GFI1Bm in either CWI-emerald (CWI-em, Wiskott Aldrich promoter) or 
CSI-emerald (CSI-em, spleen focus forming virus promoter) vectors, for low and 
high level of enforced gene expression respectively. Ev, empty vector; SIN3A, 
loading control; UT, untransduced. 
(B) Quantitative real time RT-PCR analysis of endogenous GFI1B (eGFI1B) 
expression normalized to the empty vector mRNA level (arbitarily set to 1) and 
GAPDH in K562 cells transduced with either CWI-em or CSI-em. Error bars 
indicate mean +SEM of 3 and 2 independent experiments, respectively. P value 
for GFI1Bm vs GFI1B. 
(C) Quantitative RT-PCR assay of eGFI1B expression in CD34+GFP+ primary 
cells infected with the CSI-em lentiviruses. Analysis as in Figure 2B. Error bars 
indicate mean +SEM of 3 independent infections. P value for GFI1Bm vs 
GFI1B. 
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(D) Quantitative real time RT-PCR analysis of GFI1B targets GFI1 and TGFBR3 
analyzed as in Figure 2B of K562 cells transduced with CWI-em or CSI-em 
lentiviruses, as indicated. Error bars indicate mean +SEM 3 independent 
experiments. 
(E) Diagram of human GFI1B locus; coordinates relative to ATG start codon; 
promoter (P) is pointed with a black arrow; the downstream regulatory elements 
(Reg. Elements) are shown with black boxes over DNA sequence (black 
horizontal line); grey boxes on the sequence are GFI1B exons; black boxes 
numbered 1-6 indicate the position of amplicons used in real time ChIP PCR. 
(F-G) Chromatin immunoprecipitation (ChIP) assay of lysine 4 of histone 3 
trimethylation (H3K4me3) (F) and histone 3, lysine 4 dimethylation (H3K4me2) 
(G). Numbers correspond to the  amplicons indicated in Figure 2E. Results in 
HBZ (Ŗ globin, Ŗ Gl.) and HBG (Ŋ globin, Ŋ Gl.) promoter controls are shown. 
Error bars indicate mean +SEM of 3 to 4 experiments. 
 
Figure 3. GFI1B mutant blocks erythroid differentiation and promotes 
myeloid output and cell survival in normal human primary cells. 
(A) Total GFI1B expression in adult CD34+ cells, obtained from G-CSF 
mobilized adult human peripheral blood from patients undergoing autograft 
procedures for non-hematological disorders, transduced with either GFI1B or 
GFI1Bm in CSI-emerald (CSI-em) or CWI-emerald (CWI-em) vectors. Ev, 
empty vectors. Analysis as in Figure 2B, error bars indicate mean +SEM of 2 
independent experiments. 
(B) Representative histograms showing lineage output of virally transduced 
(GFP+) adult bone marrow derived CD34+ cells (CSI-em vector) after 6 days 
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liquid culture with SCF, FLT3L, IL-3, GM-CSF, G-CSF and EPO (multipotential 
cytokines); (total number of experiments (n)= 5). Erythroid differentiation was 
assesed by surface expression of CD36 and CD235a and myeloid 
differentiation by CD13. CD36 identifies early erythroid cells as well as 
monocytes, CD235a is a specific marker of terminal erythroid differentiation. 
(C) Representative flow cytometric profiles of GFP+ cord blood CMPs following 
transduction with the indicated CSI-em viruses and liquid culture with 
multipotential cytokines for 5 days. 
(D) Myeloid and erythroid colony output from bone marrow-derived CD34+ cells 
transduced with CSI vectors carrying either GFI1B or GFI1Bm. Transduced 
cells were maintained in liquid culture with multipotential cytokines for 3 days 
before GFP+ cells were isolated, and 1000 plated in methylcellulose containing 
multipotential cytokines. Colonies were scored after a further for 15 days (in 
each experiment, identical numbers of GFP+ cells were plated, error bars 
indicate mean +SEM of 5 experiments). 
(E) CD36+/CD235a+ output from GFP+ CD34+ cells transduced with either 
GFI1B or GFI1Bm in CSI-em or CWI-em vectors following 7 days liquid culture 
with IL-3, IL-6 and EPO (mean +SEM of 3 and 5 independent experiments, 
respectively). 
(F) Annexin V staining of transduced (CSI-em) CD34+ cells after 5 days in the 
absence of cytokines (mean +SEM of 3 experiments). 
(G) Representative histograms showing annexin V and Hoechst 33258 staining.  
*p<0.05; **p<0.005; ***p<0.0005. 
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Figure 4. GFI1B-GFI1Bm versus SPI1 cross regulation in normal and AML 
cells suggest that GFI1Bm functions through SPI1 deregulation. 
(A) Expression of SPI1, GFI1B and GATA1 in 285 unselected AML patients. 
Pairwise correlations between samples calculated on the basis of 2856 probe 
sets are displayed as described.30 Colors of boxes visualize Pearson’s 
correlation coefficient: red indicates higher positive correlation, blue indicates 
higher negative correlation. 16 clusters of AMLs samples with similar gene 
expression profiles were uncovered.30 The histograms next to each sample 
represent levels of SPI1, GFI1B and GATA1 mRNA expression for each patient 
sample. 
(B) The transcription factor GFI1B-SPI1 interaction circuit for a heteroygous 
GFI1B mutation. The dashed lines indicate the effect of mutation on the GFI1B 
repression of itself, the GFI1B mutant and SPI1. 
(C) Time series concentrations of GFI1B (blue) and SPI1 (gray) indicating the 
final steady state values. In the normal case (no mutations) the steady state is 
low for SPI1 and high for GFI1B. 
(D) Time series concentrations of GFI1B wild-type (blue), GFI1B mutant (red) 
and SPI1 (gray) mRNA showing the effect of the GFI1B mutation. The presence 
of the GFI1B mutant allele results in elevated expression of SPI1 and both 
mutant and wild-type GFI1B. The expression values of the transcription factors 
in this circuit are increased as compared to the initial conditions. Note that 
GFI1B and SPI1 curves are superimposed. The dynamical equations underlying 
panels (C) and (D) are described in the Supplementary Methods. 
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(E) Quantitative RT-PCR assay of SPI1 relative (R) expression in K562 cells 
infected with the CWI-em viruses and plotted as in Figure 2B. Error bars 
indicate mean +STD of 2 independent experiments *p<0.05 (0.0079). 
(F) Quantitative RT-PCR of SPI1 expression in GFP+/CD13-/CD235a- cells 
derived from adult CD34+ cells infected with CSI-em viruses and plotted as in 
Figure 2B.  
(G) Cross-species sequence alignment at the SPI1 promoter. Solid bar 
indicates the core motif of GFI1B binding site (AATC). The coordinates of the 
start of this sequence in human, GRCh/hg19, (H); and mouse, NCBI37/mm9, 
(M) are shown on top of the alignment. H, human (Homo sapiens); M, mouse 
(Mus musculus); D, dog (Canis familiaris); C, cow (Bos taurus); Op, opossum 
(Monodelphis domestica). 
(H) ChIP assay with antibody anti-GFI1B (M-GFI1B) and no antibody control 
(K562 cells, CSI vectors). Results at SPI1 promoter, GFI1B promoter (positive 
control) and HBZ (Ŗ globin, Ŗ Gl.) and HBG (Ŋ globin, Ŋ Gl.) promoter (negative 
controls) are shown. Error bars indicate mean +SEM of 2 independent 
experiments, these data was confirmed in K562 cells transduced with CWI Ev 
and overexpresing GFI1B (data not shown). *p<0.05, **p<0.005. 
 
Figure 5. SPI1 regulated gene CD4 expression correlates with SPI1 levels 
in AML and increases in the presence of GFI1Bm. In contrast, the 
expression of positive regulator of erythroid and megakaryocytic 
differentiation MLLT3 is increased by high GFI1B expression and reduced 
by GFI1Bm. 
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(A) Correlation view of 285 AML patients. See legend Figure 4A; mRNA 
expression of SPI1 and CD4 is shown. 
(B-C) Representative histograms (B) and bar charts (C) showing CD4 
expression by the progeny of adult CD34+ cells transduced with either GFI1B or 
GFI1Bm in CSI-em and maintained in liquid culture with multipotential cytokines 
for 5 days; Ev, empty vector; error bars indicate mean +SEM of 3 experiments. 
(D) Correlation view of 285 AML patients, see legend Figure 4A; mRNA 
expression of GFI1B, MLLT3 and SPI1 is shown. Correlation between MLLT3 
and GFI1B: Both are low in clusters 5, 9, 11, 12 and 13. Both are high in 
clusters 7, 8 and 10. Anti-correlation with SPI1: SPI1 is higher in the clusters 
with low GFI1B/MLLT3, i.e. clusters 5, 9 and 11, 12 and 13. SPI1 is low in the 
clusters with high GFI1B/MLLT3, i.e. clusters 7, 8 and 10. In other clusters 
expression of all three genes is intermediate. 
(E-F) Quantitative real time RT-PCR analysis of MLLT3 in K562 (E) and GFP+ 
adult CD34+ (F) cells transduced with CSI-em lentiviruses. Expression 
normalized relative to the CSI-em mRNA level (set to 1). Number of 
experiments (n) is indicated, **p<0.005. 
 
Figure 6. GFI1B D262N differentiation disruption is greatly restored by 
knockdown of SPI1.  
(A) Quantitative RT-PCR assay of SPI1 expression in adult 
GFP+/CD13+/CD235a- cells transduced with either control (SLX) or SPI1 
hairpin (KD) vectors. Analysis as before. 
(B) Quantitative RT-PCR analysis of SPI1 and GFI1B relative expression (R. 
Expression) in K562 transduced with control vector (SLX), and SPI1 hairpin24 
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(KD) vectors carrying either GFI1B (KD/GFI1B) or GFI1Bm (KD/GFI1Bm) 
transgenes. 
(C) Analysis of erythroid output (assessed with erythroid markers CD71 and 
CD235a) from adult CD34+ cells from G-CSF mobilized peripheral blood with 
CSI-em and SLX-SPI1 knock down (KD) lentiviruses, over-expressing either 
wild-type (GFI1B) or mutant (GFI1Bm), or CSI-em empty vector (Ev) and SLX 
controls, and maintained in liquid culture for 5 days with multipotential 
cytokines. Histograms representative of 5 independent experiments. 
(D) Representative histograms (left) showing CD13 and CD235a expression in 
the progeny of normal adult CD34+ cells transduced with CSI-em and SLX-
SPI1 knock down (KD) lentiviruses, over-expressing either wild-type (GFI1B) or 
mutant (GFI1Bm) GFI1B and maintained in liquid culture with multipotential 
cytokines for 5 days. Quantitation of CD235a+ expression from 5 such 
experiments (right); error bars indicate mean +SEM, *p<0.05. 
(E) Representative histograms (left) showing CD13 and CD235a expression in 
the progeny of CMPs transduced as in (D) and maintained in liquid culture with 
multipotential cytokines for 5 days. Quantitation of CD235a+ expression from 2 
such experiments (right); error bars indicate mean +SEM, *p<0.05. 
(F) Left, representative flow cytometric profiles showing CD4 expression in the 
progeny of normal adult CD34+ cells transduced as indicated. Right, 
quantitation of CD4+ expression from 3 such experiments; error bars indicate 
mean +SEM. 
 
 
 
Highlights: 
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1. Novel mutation in GFI1B (D262N) associated with transition to AML from 
MDS 
2. GFI1B-D262N promotes myeloid versus erythroid output and enhances 
cell-survival 
3. SPI1 (PU.1) is a direct target of GFI1B & GFI1B-D262N dysregulates 
SPI1 expression 
4. Biological impact of the GFI1B-D262N mutation is routed through SPI1 
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